Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review

被引：23

作者：

Zhu, Tian Hao ^{[1
]}

Nakamura, Mio ^{[2
]}

Abrouk, Michael ^{[3
]}

Farahnik, Benjamin ^{[4
]}

Koo, John ^{[2
]}

Bhutani, Tina ^{[2
]}

机构：

[1] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA

[2] Univ Calif San Francisco, Dept Dermatol, Psoriasis & Skin Treatment Ctr, San Francisco, CA 94143 USA

[3] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA

[4] Univ Vermont, Coll Med, Burlington, VT USA

来源：

JOURNAL OF DERMATOLOGICAL TREATMENT | 2016年 / 27卷 / 05期

关键词：

Psoriasis; tumor necrosis factor-inhibitor; adalimumab; etanercept; infliximab; demyelinating disorder; adverse event; NECROSIS-FACTOR-ALPHA; SEVERE PLAQUE PSORIASIS; RANDOMIZED CONTROLLED-TRIAL; LONG-TERM; DOUBLE-BLIND; OPEN-LABEL; PHASE-III; INFLIXIMAB MONOTHERAPY; SURVEILLANCE REGISTRY; ETANERCEPT TREATMENT;

D O I：

10.3109/09546634.2015.1136385

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background: Tumor necrosis factor- inhibitors (TNFi) are the most widely used systemic treatments for patients with psoriasis and psoriatic arthritis. There currently exists a U.S. Food and Drug Administration issued warning label on all TNFi for rare cases of new onset or exacerbation of central nervous system demyelinating disorders. The aim of this review was to update the incidence of TNFi-induced demyelinating diseases. Methods: Pubmed database was searched for safety data regarding demyelinating disease secondary to TNFi therapy prescribed for psoriasis. Results: In clinical trials: 6990 patients had received treatment with etanercept with one reported case of multiple sclerosis; 5204 patients were treated with adalimumab with no cases identified and 2322 patients were treated with infliximab with one case of demyelinating polyneuropathy. Outside of clinical trials: 19 individual cases of demyelinating disorders from TNFi treatment have been reported. Conclusion: Although there is potential for TNF blockade to lead to demyelination of the central and peripheral nervous systems, the results of the present review suggest that demyelinating diseases associated with TNFi are extremely rare. TNFi are not recommended for use in patients with a personal history of demyelinating disease. However, with clinical vigilance and individualized treatment regimen, TNFi may be safe for use in other patients.

引用

页码：406 / 413

页数：8

共 74 条

[31] OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results [J].

Kimball, Alexa B. ;

Rothman, Kenneth J. ;

Kricorian, Gregory ;

Pariser, David ;

Yamauchi, Paul S. ;

Menter, Alan ;

Teller, Craig F. ;

Aras, Girish ;

Accortt, Neil A. ;

Hooper, Michele ;

Rice, Kara Creamer ;

Gelfand, Joel M. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (01) :115-122

[32] Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial [J].

Kimball, Alexa B. ;

Gordon, Kenneth B. ;

Langley, Richard G. ;

Menter, Alan ;

Perdok, Renee J. ;

Valdes, Joaquin .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) :263-274

[33] Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis [J].

Krueger, G ;

Callis, K .

ARCHIVES OF DERMATOLOGY, 2004, 140 (02) :218-225

[34] A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis [J].

Lebwohl, Mark G. ;

Kircik, Leon ;

Duffin, Kristina Callis ;

Pariser, David ;

Hooper, Michele ;

Wenkert, Deborah ;

Thompson, Elizabeth H. Z. ;

Yang, Jun ;

Kricorian, Greg ;

Koo, John .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 69 (03) :385-392

[35] Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study [J].

Leonardi, C. ;

Sobell, J. M. ;

Crowley, J. J. ;

Mrowietz, U. ;

Bao, Y. ;

Mulani, P. M. ;

Gu, Y. ;

Okun, M. M. .

BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (03) :658-667

[36] Etanercept as monotherapy in patients with psoriasis [J].

Leonardi, CL ;

Powers, JL ;

Matheson, RT ;

Goffe, BS ;

Zitnik, R ;

Wang, A ;

Gottlieb, AB ;

Bagel, J ;

Camisa, C ;

Caro, I ;

DiGiovanna, JJ ;

Dunlap, FF ;

Elewski, BE ;

Gribetz, CE ;

Farber, HF ;

Feldman, SR ;

Frankel, EH ;

Gaspari, AA ;

Goodman, JJ ;

Gordon, KB ;

Hampel, FC ;

Herdener, RS ;

Hoffman, MD ;

Humeniuk, JM ;

Johnson, SM ;

Kang, S ;

Kimball, AB ;

Kirsner, RS ;

Korman, NJ ;

Krueger, GG ;

Kuwahara, RT ;

Lebwohl, M ;

Ling, MR ;

Liu, DC ;

Lowe, N ;

McCall, CO ;

Menter, A ;

Miller, BH ;

Moore, JK ;

Nayak, AS ;

Ratner, PH ;

Savin, RC ;

Shupack, JL ;

Smith, SL ;

Stone, SP ;

Swinehart, JM ;

Taborn, J ;

Tschen, EH ;

Weinstein, GD ;

Werth, VP .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :2014-2022

[37] Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet Efficacy and Safety Results From REACH, a Randomized, Placebo-Controlled, Double-blind Trial [J].

Leonardi, Craig ;

Langley, Richard G. ;

Papp, Kim ;

Tyring, Stephen K. ;

Wasel, Norman ;

Vender, Ronald ;

Unnebrink, Kristina ;

Gupta, Shiraz R. ;

Valdecantos, Wendell C. ;

Bagel, Jerry .

ARCHIVES OF DERMATOLOGY, 2011, 147 (04) :429-436

[38]

Leonardi C, 2010, J DRUGS DERMATOL, V9, P928

[39] TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination [J].

Liu, JL ;

Marino, MW ;

Wong, G ;

Grail, D ;

Dunn, A ;

Bettadapura, J ;

Slavin, AJ ;

Old, L ;

Bernard, CCA .

NATURE MEDICINE, 1998, 4 (01) :78-83

[40]

Lozeron P, 2009, ARCH NEUROL-CHICAGO, V66, P490, DOI 10.1001/archneurol.2009.11

← 1 2 3 4 5 6 7 8 →